FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004920434> ?p ?o ?g. }

• W2004920434 endingPage "968" @default.
• W2004920434 startingPage "958" @default.
• W2004920434 abstract "Combination therapy is increasingly being utilized for the treatment of metastatic breast cancer. However, coadministration of drugs, particularly agents that are substrates for or inhibitors of p-glycoprotein, can result in increased tissue toxicity. Unfortunately, determination of levels of chemotherapeutics in human tissues is challenging, and plasma drug concentrations are not always indicative of tissue toxicokinetics or toxicodynamics, especially when tissue penetration is altered. The aim of the present work was to determine whether concomitant administration of compounds currently being combined in clinical trials for metastatic breast cancer treatment alters plasma and tissue pharmacokinetics in mice if both agents are p-glycoprotein substrates and/or inhibitors. Accordingly, we investigated the pharmacokinetic interactions of the classic cytotoxics and p-glycoprotein substrates docetaxel and doxorubicin when administered concurrently with the targeted agent and p-glycoprotein inhibitor lapatinib. Our time-course plasma and tissue distribution studies showed that coadministration of lapatinib with doxorubicin did not appreciably alter the pharmacokinetics of this anthracycline in the plasma or six tissues evaluated in mice, presumably because, at doses relevant to human exposure, lapatinib inhibition of p-glycoprotein did not significantly alter doxorubicin transport out of these tissue compartments. However, combining lapatinib with docetaxel significantly increased intestinal exposure to this chemotherapeutic, which has clinical implications for enhancing gastrointestinal toxicity. The significant lapatinib–docetaxel interaction is likely CYP3A4-mediated, suggesting that caution should be exercised when this combination is administered, particularly to patients with compromised CYP3A activity, and recipients should be monitored closely for enhanced toxicity, particularly for adverse effects on the intestine." @default.
• W2004920434 created "2016-06-24" @default.
• W2004920434 creator A5053075566 @default.
• W2004920434 creator A5072152051 @default.
• W2004920434 date "2013-10-01" @default.
• W2004920434 modified "2023-10-18" @default.
• W2004920434 title "Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice" @default.
• W2004920434 cites W1858200607 @default.
• W2004920434 cites W1964470226 @default.
• W2004920434 cites W1965295365 @default.
• W2004920434 cites W1996735384 @default.
• W2004920434 cites W1999078836 @default.
• W2004920434 cites W2000200648 @default.
• W2004920434 cites W2010831381 @default.
• W2004920434 cites W2013492426 @default.
• W2004920434 cites W2019747410 @default.
• W2004920434 cites W2022263713 @default.
• W2004920434 cites W2028533496 @default.
• W2004920434 cites W2032268660 @default.
• W2004920434 cites W2048779347 @default.
• W2004920434 cites W2051022152 @default.
• W2004920434 cites W2051705068 @default.
• W2004920434 cites W2073728815 @default.
• W2004920434 cites W2076708539 @default.
• W2004920434 cites W2083356003 @default.
• W2004920434 cites W2090892185 @default.
• W2004920434 cites W2096074600 @default.
• W2004920434 cites W2097706195 @default.
• W2004920434 cites W2098064809 @default.
• W2004920434 cites W2104354032 @default.
• W2004920434 cites W2110935327 @default.
• W2004920434 cites W2120869872 @default.
• W2004920434 cites W2128804411 @default.
• W2004920434 cites W2129488628 @default.
• W2004920434 cites W2131970746 @default.
• W2004920434 cites W2132865753 @default.
• W2004920434 cites W2150549589 @default.
• W2004920434 cites W2151193856 @default.
• W2004920434 cites W2153517678 @default.
• W2004920434 cites W2155974380 @default.
• W2004920434 cites W2161097683 @default.
• W2004920434 cites W2414089185 @default.
• W2004920434 doi "https://doi.org/10.1097/cad.0b013e3283645e1a" @default.
• W2004920434 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4694043" @default.
• W2004920434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23928571" @default.
• W2004920434 hasPublicationYear "2013" @default.
• W2004920434 type Work @default.
• W2004920434 sameAs 2004920434 @default.
• W2004920434 citedByCount "10" @default.
• W2004920434 countsByYear W20049204342016 @default.
• W2004920434 countsByYear W20049204342017 @default.
• W2004920434 countsByYear W20049204342018 @default.
• W2004920434 countsByYear W20049204342019 @default.
• W2004920434 countsByYear W20049204342020 @default.
• W2004920434 countsByYear W20049204342021 @default.
• W2004920434 countsByYear W20049204342023 @default.
• W2004920434 crossrefType "journal-article" @default.
• W2004920434 hasAuthorship W2004920434A5053075566 @default.
• W2004920434 hasAuthorship W2004920434A5072152051 @default.
• W2004920434 hasBestOaLocation W20049204342 @default.
• W2004920434 hasConcept C112705442 @default.
• W2004920434 hasConcept C121608353 @default.
• W2004920434 hasConcept C126322002 @default.
• W2004920434 hasConcept C133936738 @default.
• W2004920434 hasConcept C185592680 @default.
• W2004920434 hasConcept C2775930923 @default.
• W2004920434 hasConcept C2776694085 @default.
• W2004920434 hasConcept C2776802502 @default.
• W2004920434 hasConcept C2777329042 @default.
• W2004920434 hasConcept C2778707650 @default.
• W2004920434 hasConcept C2779786085 @default.
• W2004920434 hasConcept C2781190966 @default.
• W2004920434 hasConcept C2781303535 @default.
• W2004920434 hasConcept C29730261 @default.
• W2004920434 hasConcept C501593827 @default.
• W2004920434 hasConcept C530470458 @default.
• W2004920434 hasConcept C55493867 @default.
• W2004920434 hasConcept C71924100 @default.
• W2004920434 hasConcept C98274493 @default.
• W2004920434 hasConceptScore W2004920434C112705442 @default.
• W2004920434 hasConceptScore W2004920434C121608353 @default.
• W2004920434 hasConceptScore W2004920434C126322002 @default.
• W2004920434 hasConceptScore W2004920434C133936738 @default.
• W2004920434 hasConceptScore W2004920434C185592680 @default.
• W2004920434 hasConceptScore W2004920434C2775930923 @default.
• W2004920434 hasConceptScore W2004920434C2776694085 @default.
• W2004920434 hasConceptScore W2004920434C2776802502 @default.
• W2004920434 hasConceptScore W2004920434C2777329042 @default.
• W2004920434 hasConceptScore W2004920434C2778707650 @default.
• W2004920434 hasConceptScore W2004920434C2779786085 @default.
• W2004920434 hasConceptScore W2004920434C2781190966 @default.
• W2004920434 hasConceptScore W2004920434C2781303535 @default.
• W2004920434 hasConceptScore W2004920434C29730261 @default.
• W2004920434 hasConceptScore W2004920434C501593827 @default.
• W2004920434 hasConceptScore W2004920434C530470458 @default.
• W2004920434 hasConceptScore W2004920434C55493867 @default.
• W2004920434 hasConceptScore W2004920434C71924100 @default.
• W2004920434 hasConceptScore W2004920434C98274493 @default.

• next